Brent O. Davis, M.D., F.A.C.C. - Professional Research

Principal Investigator

• APPRAISE-1 (CV185023) A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome.
• IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) A Multicenter, double-blind, randomized study to establish the clinical benefit and safety of Vytorin (ezetimibe/simvastatin tablet) vs. simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome (ACS)

• Randomized evaluation of long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY)
• Gemini Angioplasty and Arterial Measurement Evaluation (GAAME)- An evaluation of the Metricath Gemini System, a percutaneous interventional device intended to make arterial lumen measurements and perform percutaneous transluminal angioplasty dilations.
  
• ENDEAVOR IV - A randomized, controlled trial of the Medtronic Endeavor drug (ABT-578) eluting coronary stent system versus the Taxus paclitaxel-eluting coronary stent system in De Novo native coronary artery lesions
• TENACITY – A randomized, Multicenter, double-blind, Abciximab-controlled study to evaluate the efficacy of Tirofiban versus Abciximab among subjects undergoing percutaneous coronary intervention with stent placement receiving Bivalirudin or Heparin. Protocol #0120-0401
• EARLY ACS – Early Glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome: A randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded Eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome
• TIMI 38 – A comparison of (CS-747) and Clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention
• FUSION II – Follow-up Serial Infusions of Natrecor® (nesiritide) for the Management of Patients with Heart Failure
• CURRENT / OASIS 7 – Clopidogrel optimal loading dose usage to reduce recurrent events / optimal antiplatelet strategy for interventions
• CHAMPION Platform – A clinical trial comparing treatment with Cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention (Protocol No. TMC-CAN-05-03)
• TOPCAT – Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist – A Multi-center, International, Randomized, Double-blind, Placebo-controlled Trial of the Aldosterone Antagonist, Spironolactone, in Adults with Heart Failure and Left Ventricular Ejection Fraction of at Least 45%